Skip to Main Content
Contribute Try STAT+ Today

Avanir Pharmaceuticals agreed to pay $116 million to settle civil and criminal charges of allegedly bribing doctors to prescribe Nuedexta, a drug for treating uncontrollable laughing and crying, and also misleading nursing homes into giving the medicine to patients with dementia even though it was not approved for that purpose.

At the same time, two Ohio doctors were indicted for allegedly accepting kickbacks that included money, meals, office equipment, travel expenses, and firearms training in exchange for writing Nuedexta prescriptions for people who did not need the medication. The condition Nuedexta is used to treat is called pseudobulbar affect. The U.S. Department of Justice also indicted two former Avanir sales reps for allegedly providing the kickbacks.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.